Pancreatic Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Pancreatic Cancer, including details on symptoms, causes, treatment, information.

Volume 6 (2009), Issue 8 (August)

1. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival.
   Ann Surg, 250(2): 282-7. [Abstract] [Full-text]
2. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
   J Gastrointest Surg, 13(9): 1699-706. [Abstract] [Full-text]
3. Development of a VX2 pancreatic cancer model in rabbits: a pilot study.
   J Vasc Interv Radiol, 20(8): 1075-82. [Abstract] [Full-text]
4. Is blind pancreaticoduodenectomy justified for patients with ampullary neoplasms?
   J Gastrointest Surg, 13(9): 1666-73. [Abstract] [Full-text]
5. A central pancreatectomy for benign or low-grade malignant neoplasms.
   J Gastrointest Surg, 13(9): 1659-65. [Abstract] [Full-text]
6. (-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2.
   Mol Pharm, 6(4): 1152-9. [Abstract] [Full-text]
7. Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer.
   Cancer Lett, 283(2): 119-24. [Abstract] [Full-text]
8. Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
   Anat Rec (Hoboken), 292(8): 1122-7. [Abstract] [Full-text]
9. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
   Ann Oncol, 20(8): 1387-96. [Abstract] [Full-text]
10. HOX D13 expression across 79 tumor tissue types.
    Int J Cancer, 125(7): 1532-41. [Abstract] [Full-text]
11. Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.
    Ann Oncol, 20(8): 1369-74. [Abstract] [Full-text]
12. Pancreatic cancer: current and future treatment strategies.
    Cancer Treat Rev, 35(5): 431-6. [Abstract] [Full-text]
13. Artificial sweeteners and the risk of gastric, pancreatic, and endometrial cancers in Italy.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2235-8. [Abstract] [Full-text]
14. Passive smoking and pancreatic cancer in women: a prospective cohort study.
    Cancer Epidemiol Biomarkers Prev, 18(8): 2292-6. [Abstract] [Full-text]
15. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    J Clin Oncol, 27(23): 3778-85. [Abstract] [Full-text]
16. Pancreatic tumor motion on a single planning 4D-CT does not correlate with intrafraction tumor motion during treatment.
    Am J Clin Oncol, 32(4): 364-8. [Abstract] [Full-text]
17. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Am J Clin Oncol, 32(4): 348-52. [Abstract] [Full-text]
18. Differential diagnosis of cystic tumors of the pancreas by endoscopic ultrasonography.
    Endoscopy, 41(8): 684-9. [Abstract] [Full-text]
19. A comprehensive study of Sansalvamide A derivatives: The structure-activity relationships of 78 derivatives in two pancreatic cancer cell lines.
    Bioorg Med Chem, 17(16): 5806-25. [Abstract] [Full-text]
20. Correcting serum concentrations of organochlorine compounds by lipids: alternatives to the organochlorine/total lipids ratio.
    Environ Int, 35(7): 1080-5. [Abstract] [Full-text]
21. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
    Cancer, 115(16): 3640-50. [Abstract] [Full-text]
22. Preliminary experience with the hanging maneuver for pancreaticoduodenectomy.
    Eur J Surg Oncol, 35(9): 1006-10. [Abstract] [Full-text]
23. let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression.
    Hum Gene Ther, 20(8): 831-44. [Abstract] [Full-text]
24. Central pancreatectomy for benign tumors of the neck and body of the pancreas: report of eight cases.
    J Surg Oncol, 100(3): 273-6. [Abstract] [Full-text]
25. Staging for locally advanced pancreatic cancer.
    Eur J Surg Oncol, 35(9): 963-8. [Abstract] [Full-text]
26. Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.
    Br J Cancer, 101(4): 637-44. [Abstract] [Full-text]
27. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
    Oncogene, 28(32): 2903-9. [Abstract] [Full-text]
28. Serous microcystic adenoma of the pancreas.
    Indian J Pathol Microbiol, 52(3): 408-10. [Abstract] [Full-text]
29. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth.
    Cancer Res, 69(16): 6539-45. [Abstract] [Full-text]
30. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
    Cancer Res, 69(16): 6704-12. [Abstract] [Full-text]
31. The impact of obesity on outcomes following pancreatectomy for malignancy.
    Ann Surg Oncol, 16(9): 2565-9. [Abstract] [Full-text]
32. CD74 is a novel prognostic factor for patients with pancreatic cancer receiving multimodal therapy.
    Ann Surg Oncol, 16(9): 2531-8. [Abstract] [Full-text]
33. Clinical fate of branch duct and mixed forms of intraductal papillary mucinous neoplasia of the pancreas.
    J Gastroenterol Hepatol, 24(7): 1211-7. [Abstract] [Full-text]
34. Management of the rare entity of primary pancreatic cystic neoplasms.
    J Gastroenterol Hepatol, 24(7): 1203-10. [Abstract] [Full-text]
35. High frequency of down-regulation of E-cadherin detected in benign sporadic insulinomas by multiplex ligation-dependent probe amplification.
    Hum Pathol, 40(9): 1336-41. [Abstract] [Full-text]
36. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
    Hum Pathol, 40(9): 1262-8. [Abstract] [Full-text]
37. Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts.
    Cancer Gene Ther, 16(9): 731-40. [Abstract] [Full-text]
38. In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
    Cancer Chemother Pharmacol, 64(5): 1009-20. [Abstract] [Full-text]
39. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma.
    Immunology, 128(1): 141-9. [Abstract] [Full-text]
40. Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.
    Immunology, 128(1): 134-40. [Abstract] [Full-text]
41. Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
    Cancer Chemother Pharmacol, 64(6): 1253-9. [Abstract] [Full-text]
42. Experimental study of combination therapy with S-1 against pancreatic cancer.
    Cancer Chemother Pharmacol, 64(6): 1211-9. [Abstract] [Full-text]
43. Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
    Cancer Chemother Pharmacol, 64(6): 1173-9. [Abstract] [Full-text]
44. Pancreatic resection in octogenarians.
    J Surg Res, 156(1): 129-32. [Abstract] [Full-text]
45. Tumor-derived pancreatic stellate cells promote pancreatic cancer cell invasion through release of thrombospondin-2.
    J Surg Res, 156(1): 155-60. [Abstract] [Full-text]
46. Mutations in the mitochondrial genome confer resistance of cancer cells to anticancer drugs.
    Cancer Sci, 100(9): 1680-7. [Abstract] [Full-text]
47. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
    Cancer Sci, 100(9): 1623-30. [Abstract] [Full-text]
48. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer.
    J Cell Mol Med, 13(7): 1221-7. [Abstract] [Full-text]
49. Proteomic identification of an MHC-binding peptidome from pancreas and breast cancer cell lines.
    Mol Immunol, 46(15): 2931-7. [Abstract] [Full-text]
50. Fractures of self-expanding metallic stents in periampullary malignant biliary obstruction.
    Acta Radiol, 50(7): 730-7. [Abstract] [Full-text]
51. Synthesis and in-vitro antitumour activity of new naphthyridine derivatives on human pancreatic cancer cells.
    J Pharm Pharmacol, 61(8): 1057-66. [Abstract] [Full-text]
52. NIK is involved in constitutive activation of the alternative NF-kappaB pathway and proliferation of pancreatic cancer cells.
    Biochem Biophys Res Commun, 388(1): 96-101. [Abstract] [Full-text]
53. Pancreatic resection: a key component to reducing racial disparities in pancreatic adenocarcinoma.
    Cancer, 115(17): 3979-90. [Abstract] [Full-text]
54. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer.
    Nat Genet, 41(9): 986-90. [Abstract] [Full-text]
55. Perivascular epithelioid cell tumor (PEComa) of the pancreas: immunoelectron microscopy and review of the literature.
    Pathol Int, 59(9): 650-5. [Abstract] [Full-text]
56. Pancreatic incidentalomas: high rate of potentially malignant tumors.
    J Am Coll Surg, 209(3): 313-9. [Abstract] [Full-text]
57. Targeting of the protein interaction site between FAK and IGF-1R.
    Biochem Biophys Res Commun, 388(2): 301-5. [Abstract] [Full-text]
58. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer.
    J Clin Oncol, 27(25): 4116-23. [Abstract] [Full-text]
59. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    J Clin Oncol, 27(25): 4096-102. [Abstract] [Full-text]
60. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.
    Am J Surg, 198(3): 333-9. [Abstract] [Full-text]
61. Comparison of laparoscopy-assisted and open pylorus-preserving pancreaticoduodenectomy for periampullary disease.
    Am J Surg, 198(3): 445-9. [Abstract] [Full-text]

© 2004-2010 Pancreatic Cancer Research Today. All Rights Reserved.